|
WO2011087627A1
|
|
Stabilized interferon formulations
|
|
WO2011005502A2
|
|
Methods and compositions for the cryopreservation of duckweed
|
|
EP2435562A1
|
|
Compositions and methods for production of aglycosylated plasminogen
|
|
US2010209966A1
|
|
Aseptic bioreactor system for processing biological materials
|
|
BRPI1008441A2
|
|
humanized antibody, pharmaceutical composition, method for treating and preventing a subject b-cell disorder, humanized anti-cd-20 antibody composition, isolated nucleic acid and host cell.
|
|
CN101820887A
|
|
Controlled release interferon drug products and treatment of hcv infection using sam
|
|
US2009060921A1
|
|
Glycan-optimized anti-cd20 antibodies
|
|
KR20080094918A
|
|
Compositions and methods for humanization and optimization of n-glycans in plants
|
|
CN101421403A
|
|
Compositions and methods for humanization and optimization of n-glycans in plants
|
|
CN101395177A
|
|
Expression control elements from the lemnaceae family
|
|
US2005262592A1
|
|
Expression of plasminogen and microplasminogen in duck weed
|
|
US2007128162A1
|
|
C-terminally truncated interferon alpha variants
|
|
US2004261148A1
|
|
Expression of monoclonal antibodies in duckweed
|
|
US2006195946A1
|
|
Expression of biologically active polypeptides in duckweed
|
